Related Experiment Videos
Antiangiogenic therapy in brain tumor models
H J Bernsen1, A J van der Kogel
1Institute of Radiotherapy, University of Nijmegen, The Netherlands.
Abstract:
The prognosis of patients with malignant brain tumors remains poor despite new developments in neurosurgery, chemotherapy and radiotherapy. Malignant gliomas are highly vascularized, and there is ample evidence that their growth is angiogenesis-dependent. Therefore, new therapeutic approaches often include the inhibition of angiogenesis. In this review, experimental studies of antiangiogenic agents in brain tumor models are summarized. The results of these experiments as well as potential pitfalls in extrapolation to the clinic are discussed.
Insights
Malignant brain tumors are poor-prognosis diseases dependent on angiogenesis. This review summarizes antiangiogenic agents in brain tumor models, discussing experimental results and clinical translation challenges.
Area of Science:
- Neuro-oncology
- Cancer biology
- Angiogenesis research
Background:
- Malignant brain tumors, particularly gliomas, exhibit poor patient prognosis despite advances in standard treatments.
- Malignant gliomas are characterized by high vascularization and angiogenesis-dependent growth.
- Angiogenesis inhibition is a key strategy in developing novel therapeutic approaches for brain tumors.
Purpose of the Study:
- To review experimental studies on antiangiogenic agents in brain tumor models.
- To discuss the efficacy of these agents in preclinical settings.
- To identify potential challenges in translating these findings to clinical practice.
Main Methods:
- Literature review of experimental studies involving antiangiogenic agents in brain tumor models.
- Summary of results from preclinical investigations.
- Analysis of the relevance and limitations of extrapolating animal model data to human patients.
Main Results:
- Experimental studies demonstrate the potential of antiangiogenic agents in inhibiting tumor growth in preclinical brain tumor models.
- Evidence suggests that targeting angiogenesis can impact malignant glioma progression.
- Variability in study designs and models necessitates careful interpretation of results.
Conclusions:
- Antiangiogenic strategies show promise for treating malignant brain tumors, based on preclinical data.
- Translating the success of antiangiogenic agents from experimental models to clinical efficacy requires addressing significant challenges.
- Further research is needed to optimize antiangiogenic therapies for improved patient outcomes in neuro-oncology.